News

Cancer

BridgeBio Pharma Inks Licensing Deal With Bristol Myers Squibb Worth up to $905 Million

Edward Kim | Equities.com |

BMY will pay BBIO $90 million in upfront cash.


Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins

Edward Kim | Equities.com |

The AstraZeneca deal continues to be a good one for Innate Pharma, year after year.


Cytovia Therapeutics To Go Public Via $600 Million SPAC Merger

Edward Kim | Equities.com |

The company will merge with Isleworth Healthcare Acquisition Corp.


Coeptis Therapeutics To Merge With SPAC, Uplist to Nasdaq

Edward Kim | Equities.com |

Coeptis is developing novel cell therapy platforms for cancer.


Affimed Raises $90 Million in Follow-on Equity Offering

Edward Kim | Equities.com |

Image source: Affimed

Affimed (AFMD) announced 22,500,000 of its common shares at a public offering price of $4.00

 

 

 

Investment thesis

 

_____

Source: Equities News

...


Fusion Pharmaceuticals Closes $75 Million Credit Facility With Oxford Finance

Edward Kim | Equities.com |

Oxford provides senior debt to life sciences and healthcare services companies worldwide.


Sensus Posts Record Fourth Quarter, Beats Top and Bottom Line Estimates

Edward Kim | Equities.com |

Sensus posted revenues of $13.0 million, up 156% over the prior year's Q4.


MacroGenics Signs $586 Million Licensing Deal With Synaffix for Antibody-Drug Conjugate Technology

Edward Kim | Equities.com |

The appetite for next generation breast cancer therapies continues to grow unabated.


TG Therapeutics Tumbles 40% on Partial Clinical Trial Hold

Edward Kim | Equities.com |

Shares of TG Therapeutics (TGTX) got slammed Thursday after CEO Michael Weiss disclosed that the FDA had placed a partial hold on the company's Phase 3 trial  lost 40.5% of their value Thursday on nevaluating the investigational U2 combination (UKONIQ® (umbralisib) and ublituximab) compared to the control arm of obinutuzumab plus chlorambucil and that the FDA imposed a partial clinical hold on select studies of U2 and its components for chronic lymphocytic leukemia (CLL) ...


Sponsored Financial Content

Market Movers